集団レベルにおける消化管通過時間に関する研究 (GITTPop)
集団レベルにおける胃腸通過時間:横断研究
The goal of this study is to investigate the baseline of gastrointestinal transit time (GITT) and explore its relationship with other health indicators in 932 healthy adult volunteers.
The main questions it aims to answer are:
What are the population-level baseline values for GITT using the blue dye method? How is GITT associated with key physiological parameters including blood metabolic markers, life style, and stool characteristics?
Participants will:
Consume a standardized blue dye muffin after overnight fasting at the research center; Offer a finger prock blood samples for metabolic profiling; Offer a saliva sample for whole exome sequencing analysis; Collect stool samples for moisture measurement; Complete detailed questionnaires on diet, lifestyle, and bowel habits; Record the time of first blue stool appearance to determine GITT.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This explorative study is designed as a cross-sectional investigation aimed at establishing population-level reference values for gastrointestinal transit time (GITT). Adult participants from the general population will undergo GITT measurement using the blue-dye method. This muffin contains blue colorant that cannot be absorbed; after ingestion, it passes through the entire gastrointestinal tract and is eventually excreted in feces. Following a two-day lifestyle standardization period (including dietary and activity guidance) to minimize potential confounding effects on gastrointestinal motility, participants will attend a clinical visit where they will ingest a blue muffin. GITT will be determined by measuring both the time interval between ingestion of the blue muffin and the first appearance of blue-colored stool, and the duration from its first appearance to its complete disappearance.
The blue muffin method has been well-established in previous research for GITT assessment. Building upon the methodology developed by Berry et al., we will introduce stricter pre-test condition controls (includes dietary advice and lifestyle recommendations) and optimized the blue muffin formulation. These improvements allow for reliable measurement with a single muffin administration, which has been evaluated through KU Leuven Health Pass in a large sample size(S-70168).
To investigate potential determinants and correlates of GITT, we will collect biochemical parameters, fecal moisture, and resting metabolic rate. We will collect saliva samples for WGS to identify key genetic variants associated with GITT and use these findings to develop a genetic risk score. Additionally, participants will complete 24-h diet record and health questionnaires assessing bowel movement, physical activity habits, stress levels, sleep quality and hydration condition for subsequent correlation analyses.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Christophe Matthys
- 電話番号:+32 016342655
- メール:christophe.matthys@uzleuven.be
研究連絡先のバックアップ
- 名前:Wei Li
- 電話番号:+32 016344539
- メール:wei.li2@kuleuven.be
研究場所
-
-
Flemish Brabant
-
Leuven、Flemish Brabant、ベルギー、3000
- 募集
- Department of Chronic Diseases and Metabolism
-
コンタクト:
- Wim Janssens
- 電話番号:+32 016252111
- メール:wim.janssens@kuleuven.be
-
コンタクト:
- Evelyne van Etten
- 電話番号:+32 016330855
- メール:evelyne.vanetten@kuleuven.be
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Healthy volunteers from the Flanders region who volunteered to participate in the research
説明
Inclusion Criteria:
- 18-65 years old
- 18.5 kg/m² ≤ BMI ≤ 25 kg/m² or BMI ≥ 30 kg/m² (people with normal weight or obesity)
- Provision of informed consent to participate.
Exclusion Criteria:
- Gastrointestinal conditions which may affect nutrient absorption or gastric emptying, including coeliac disease, Crohn's disease, previous resection of the small intestine other than bariatric surgery, gastroparesis;
- Using medications which effect gastric motility (e.g., domperidone, erythromycin, metoclopramide, prucalopride, opiates, loperamide, …)
- The ingredients of blue muffins include gluten, nuts, baking powder, sugar, vanilla extract and sunflower oil. Participants with allergies to these ingredients;
- Current diagnosis of cancer;
- Advanced organ failure, including chronic kidney disease Stage 5, liver cirrhosis Child-Pugh B or C, intestinal failure, heart failure stage D, or chronic obstructive pulmonary disease stage 4;
- Immobility;
- Neuromuscular degenerative conditions associated with muscular atrophy, such as myasthenia gravis, muscular dystrophies, fibromyalgia, or multiple Sclerosis;
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:CROSS_SECTIONAL
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Adult participants
Healthy adult participants without serious gastrointestinal diseases |
Participants will consume a regular muffin containing blue dye |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Gastrointestinal transit time
時間枠:From enrollment to the end of study at 2 weeks
|
Calculate the transit time by the recorded muffin consuming time, first blue stool appearance time and last blue stool appearance time |
From enrollment to the end of study at 2 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Height (cm)
時間枠:baseline
|
Measured using a height meter, in centimeters. |
baseline
|
|
Weight (kg)
時間枠:baseline
|
Measuring using a scale, in kg. |
baseline
|
|
BMI
時間枠:baseline
|
weight and height will be combined to report BMI in kg/m^2 |
baseline
|
|
Blood glucose (mmol/L)
時間枠:baseline
|
Measure blood glucose by CardioChek Plus in mmol/L |
baseline
|
|
Fat mass (kg)
時間枠:baseline
|
Using Bodystat quadscan 4000 to measure fat mass (kg) |
baseline
|
|
Lean body mass(kg)
時間枠:baseline
|
Using Bodystat quadscan 4000 to measure lean body mass (kg) |
baseline
|
|
Fat percentage (%)
時間枠:baseline
|
Using Bodystat quadscan 4000 to measure fat% |
baseline
|
|
Total cholesterol (mmol/L)
時間枠:baseline
|
Measuring by Mission cholesterol Meter in mmol/L |
baseline
|
|
HDL-C (mmol/L)
時間枠:baseline
|
Measuring by Mission cholesterol Meter in mmol/L |
baseline
|
|
LDL-C (mmol/L)
時間枠:baseline
|
Measuring by Mission cholesterol Meter in mmol/L |
baseline
|
|
Triglyceride (mmol/L)
時間枠:baseline
|
Measuring by Mission Cholesterol Meter in mmol/L |
baseline
|
|
Food record
時間枠:2 days after study
|
Participants record their 24-h diets through smartphone application |
2 days after study
|
|
Stool form
時間枠:baseline
|
Stool form will be evaluated by Bristol Stool Form Scale, the score is from 1 to 7, with values closer to the middle indicating more ideal stool shape. |
baseline
|
|
Hydration status
時間枠:baseline
|
Hydration status will be rated from 1 to 8 by Urine color chart, with higher numbers indicating that the body needs more water. |
baseline
|
|
Perceived level of stress
時間枠:baseline
|
The10-item Perceived Stress will be used to measures an individual's perceived level of stress over the past month. The total score ranges from 0 to 40. A higher score indicates a greater perceived level of stress. |
baseline
|
|
Sleep quality
時間枠:baseline
|
Pittsburgh Sleep Quality Index will be used to assess subjective sleep quality over the past month. The total score ranges from 0 to 21. A higher score indicates poorer sleep quality. |
baseline
|
|
Activity level
時間枠:baseline
|
The Baecke Physical Activity Questionnaire will be used to assess daily habitual physical activity, with a particular focus on work-related and exercise-related activities. It does not produce a single total score, but rather scores on three dimensions, each typically ranging from 1 to 5. On each dimension, a higher score indicates a higher level of physical activity in that area. Therefore, for assessing activity levels, a higher score is generally better. |
baseline
|
|
Whole genome sequencing (WGS)
時間枠:baseline
|
The genetic risk score will be calculated by summing the number of GITT-associated alleles carried by each participant, weighted by their estimated effect sizes. As the number and weights of the included variants will be determined during the analysis, the score does not have a predefined numerical range. The score will be standardized to a mean of 0 and a standard deviation of 1. A higher score will indicate a stronger genetic predisposition to the GITT phenotype of interest; it does not necessarily represent a better or worse health outcome. |
baseline
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- S70908
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。